ERBB2 and breast cancer: With the increasing effectiveness of neoadjuvant systemic therapy (NST), nearly 30%–70% of locally advanced breast cancer achieved pathological complete response (pCR) in primary lesion and metastatic axillary lymph nodes, notably in the triple‐negative and human epidermal growth factor receptor 2 (Her‐2)‐amplified subtypes.2, 3